PROTEINA

PROTEINA is a biotechnology startup based in South Korea, founded in 2015. The company has revolutionized protein analysis with its first-in-class protein-protein interaction (PPI) analysis platform, utilizing proprietary 'single-molecule co-immunoprecipitation' technology for quantitative measurements at the single-molecule level. This innovative platform provides unmatched accuracy and speed in analyzing PPIs, thereby paving the way for new approaches to diagnosing diseases and discovering drug candidates. In its latest funding round in July 2021, PROTEINA secured a significant KRW19.00B Series C investment, attracting a diverse group of investors including LB Investment, Aju IB Investment, Mirae Asset Venture Investment, GNTech VC, Mirae Asset Capital, Posco Capital, Timefolio Asset Management, and K-Run Ventures. This notable investment underscores the confidence of the venture capital community in the potential of PROTEINA's innovative technology and its impact on the biotechnology, healthcare, and pharmaceutical industries. With its extensive expertise in developing assays to measure targeted PPIs and the ability to model drug efficacy based on PPI metrics, PROTEINA is poised to drive significant advances in the understanding and treatment of diseases. Consequently, the company stands as a compelling investment opportunity at the forefront of revolutionizing protein analysis and contributing to advancements in the biotechnology and pharmaceutical sectors. For more information regarding PROTEINA, please visit their website at www.proteina.co.kr.